RO4929097 in Treating Patients With Metastatic Colorectal Cancer

NCT01116687 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

37

Enrollment

NIH

Sponsor class

Conditions

Recurrent Colon Cancer
Recurrent Rectal Cancer
Stage IV Colon Cancer
Stage IV Rectal Cancer

Interventions

DRUG: gamma-secretase/Notch signalling pathway inhibitor RO4929097
OTHER: laboratory biomarker analysis

Sponsor

National Cancer Institute (NCI)